Page last updated: 2024-10-31

deoxyepinephrine and Chronic Disease

deoxyepinephrine has been researched along with Chronic Disease in 20 studies

Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery, uveitis, or penetrating trauma."9.12Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma. ( Cohen, AC; Ganteris, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC; Veckeneer, M, 2006)
"The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors."9.08Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996)
"Ibopamine, a dopamine derivative suitable for oral administration, is reported to improve cardiac function in patients with chronic heart failure."9.06Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. ( Alicandri, C; Boni, E; Fariello, R; Muiesan, G; Zaninelli, A, 1989)
"To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma."7.78Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. ( Cohen, AF; Ganteris-Gerritsen, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC, 2012)
"Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony."7.73[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine]. ( Iliev, ME; Windisch, BK, 2006)
" To examine the influence of the oral dopamine agonist ibopamine on these factors, we studied 20 rats with chronic myocardial infarction and CHF, and compared them with 20 normal rats."7.69Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. ( Buikema, H; de Graeff, PA; de Smet, BJ; Girbes, AR; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1994)
"A group of 36 patients with cor pulmonale chronicum were treated for 12 months with ibopamine, a dopamine-related drug, orally active, suitable for the long-term therapy of congestive heart failure."7.67Treatment of heart failure following chronic cor pulmonale with ibopamine. ( Bianco, L; Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Sabino, F, 1988)
"50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition."7.67Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure. ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986)
"Ibopamine was given alone to 39 patients; the others were given the drug in association with digitalis, diuretics, and vasodilators."6.66Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. ( Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Rolandi, E; Sabino, F, 1989)
"Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3."6.66Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. ( Castellaccio, M; Dore, L; Ibba, GV; Sannia, L, 1986)
" A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug."6.38Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989)
"Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study."5.28Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. ( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992)
"Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated."5.27Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. ( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988)
"To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery, uveitis, or penetrating trauma."5.12Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma. ( Cohen, AC; Ganteris, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC; Veckeneer, M, 2006)
"The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors."5.08Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996)
"Ibopamine, a dopamine derivative suitable for oral administration, is reported to improve cardiac function in patients with chronic heart failure."5.06Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. ( Alicandri, C; Boni, E; Fariello, R; Muiesan, G; Zaninelli, A, 1989)
"To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma."3.78Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. ( Cohen, AF; Ganteris-Gerritsen, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC, 2012)
"Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony."3.73[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine]. ( Iliev, ME; Windisch, BK, 2006)
" To examine the influence of the oral dopamine agonist ibopamine on these factors, we studied 20 rats with chronic myocardial infarction and CHF, and compared them with 20 normal rats."3.69Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. ( Buikema, H; de Graeff, PA; de Smet, BJ; Girbes, AR; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1994)
"A group of 36 patients with cor pulmonale chronicum were treated for 12 months with ibopamine, a dopamine-related drug, orally active, suitable for the long-term therapy of congestive heart failure."3.67Treatment of heart failure following chronic cor pulmonale with ibopamine. ( Bianco, L; Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Sabino, F, 1988)
"50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition."3.67Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure. ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986)
"Ibopamine was given alone to 39 patients; the others were given the drug in association with digitalis, diuretics, and vasodilators."2.66Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. ( Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Rolandi, E; Sabino, F, 1989)
"Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3."2.66Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. ( Castellaccio, M; Dore, L; Ibba, GV; Sannia, L, 1986)
"Ibopamine treatment was ineffective in Group 2, while in Group 1 patients there was a statistically significant increase in creatinine clearance (+23% after 3 months, +31% after 6 months)."2.65Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug. ( Colí, L; Docci, D; Mosconi, G; Prandini, R; Stefoni, S; Vangelista, A, 1982)
" A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug."2.38Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989)
"Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study."1.28Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. ( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992)
"Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated."1.27Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. ( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19909 (45.00)18.7374
1990's7 (35.00)18.2507
2000's3 (15.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ganteris-Gerritsen, E1
Ugahary, LC2
Jansen, J2
Mulder, PG2
Cohen, AF1
van Meurs, JC2
Ganteris, E1
Veckeneer, M1
Cohen, AC1
Windisch, BK1
Iliev, ME1
Stefoni, S1
Docci, D1
Vangelista, A1
Mosconi, G1
Colí, L1
Prandini, R1
Walsh, JT1
Andrews, R1
Evans, A1
Cowley, AJ1
van Veldhuisen, DJ5
Brodde, OE1
van Gilst, WH2
Schulze, C1
Hegeman, H1
Anthonio, RL1
Scholtens, E2
de Graeff, PA2
Wesseling, H2
Lie, KI3
de Smet, BJ1
Buikema, H1
Girbes, AR3
Szabó, BM1
van der Burgh, PH1
Kruik, J1
Niebauer, J1
Coats, AJ1
Hillege, HL1
de Kam, PJ1
Boomsma, F1
de Zeeuw, D1
Charlesworth, A1
Hampton, JR1
Itoh, H1
Taniguchi, K1
Tsujibayashi, T1
Koike, A1
Sato, Y1
Nakamura, S1
Alicandri, C1
Fariello, R1
Boni, E1
Zaninelli, A1
Muiesan, G1
Rolandi, E1
Sabino, F2
Cantoni, V2
Ghirardi, P2
Marchetti, GV2
Cicchetti, V2
Hasenfuss, G1
Just, H1
Dei Cas, L2
Metra, M2
Nodari, S1
Riva, S1
Manca, C1
Visioli, O1
Bianco, L1
Benassi, A1
Modena, MG1
Mattioli, G1
Sannia, L1
Ibba, GV1
Castellaccio, M1
Dore, L1
Avanzini, Z1
Bellogini, GC1
Brusoni, B1
Ciampani, N1
Gazzola, U1
Maggi, GC1
Mangiavacchi, M1
Pinca, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure[NCT02133105]Phase 333 participants (Actual)Interventional2014-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for deoxyepinephrine and Chronic Disease

ArticleYear
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
    Basic research in cardiology, 1989, Volume: 84 Suppl 1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D

1989

Trials

9 trials available for deoxyepinephrine and Chronic Disease

ArticleYear
Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma.
    American journal of ophthalmology, 2006, Volume: 141, Issue:3

    Topics: Administration, Topical; Adult; Aged; Chronic Disease; Cross-Over Studies; Deoxyepinephrine; Dopamin

2006
Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug.
    Clinical nephrology, 1982, Volume: 18, Issue:4

    Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Creatinine; Deoxyepine

1982
Failure of "effective" treatment for heart failure to improve normal customary activity.
    British heart journal, 1995, Volume: 74, Issue:4

    Topics: Activities of Daily Living; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disea

1995
Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
    Journal of cardiac failure, 1996, Volume: 2, Issue:3

    Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Gas Ana

1996
Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
    Circulation, 2000, Jul-11, Volume: 102, Issue:2

    Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Output; Cardiotonic Agents; Catecholamines; Ch

2000
Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 8

    Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Digoxin; Dopamine; Double-Blind

1989
Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 8

    Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Dru

1989
The efficacy of ibopamine in long-term treatment of dilated cardiomyopathy. A clinical and instrumental evaluation.
    Arzneimittel-Forschung, 1986, Volume: 36, Issue:2A

    Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Deoxy

1986
Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.
    Arzneimittel-Forschung, 1986, Volume: 36, Issue:2A

    Topics: Adult; Cardiac Output; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Heart Failur

1986

Other Studies

10 other studies available for deoxyepinephrine and Chronic Disease

ArticleYear
Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma.
    Retina (Philadelphia, Pa.), 2012, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Deoxyepinephrine; Dopamine Agonists; Eye Injuries,

2012
[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine].
    Klinische Monatsblatter fur Augenheilkunde, 2006, Volume: 223, Issue:5

    Topics: Administration, Topical; Chronic Disease; Deoxyepinephrine; Humans; Male; Mydriatics; Ocular Hypoten

2006
Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril.
    Cardiovascular research, 1995, Volume: 30, Issue:3

    Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Chronic Dise

1995
Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure.
    Cardiovascular drugs and therapy, 1994, Volume: 8, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Chronic Disease; Deoxyepinep

1994
Treating chronic heart failure: time to take stock.
    Lancet (London, England), 1997, Apr-05, Volume: 349, Issue:9057

    Topics: Chronic Disease; Deoxyepinephrine; Dopamine Agonists; Heart Failure; Humans; Randomized Controlled T

1997
Treatment of mild heart failure: the place of diuretics and ibopamine.
    European heart journal, 1997, Volume: 18, Issue:5

    Topics: Chronic Disease; Deoxyepinephrine; Diuretics; Dopamine Agonists; Drug Therapy, Combination; Heart Fa

1997
Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
    Cardiology, 1992, Volume: 80, Issue:5-6

    Topics: Administration, Oral; Aged; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dose-Response Rel

1992
Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure.
    Cardiovascular drugs and therapy, 1988, Volume: 2, Issue:2

    Topics: Adult; Aged; Chronic Disease; Deoxyepinephrine; Drug Tolerance; Heart Failure; Humans; Male; Middle

1988
Treatment of heart failure following chronic cor pulmonale with ibopamine.
    Respiration; international review of thoracic diseases, 1988, Volume: 54 Suppl 1

    Topics: Aged; Aged, 80 and over; Chronic Disease; Deoxyepinephrine; Diuretics; Dopamine; Dose-Response Relat

1988
Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure.
    Arzneimittel-Forschung, 1986, Volume: 36, Issue:2A

    Topics: Adult; Aged; Body Weight; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Female; H

1986